search
Back to results

Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19

Primary Purpose

COVID-19

Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
0.5% Povidone Iodine
0.12% Chlorhexidine Gluconate Mouth Rinse
1% Hydrogen Peroxide
0.9% Normal Saline
Sponsored by
Ohio State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for COVID-19 focused on measuring Mouthwashes, COVID-19, Salivary Carriage, Povidone-Iodine, PCR (Polymerase Chain Reaction), Dental Aerosols

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. adults age 18-80 admitted to The Ohio State University Medical Center,
  2. diagnosis of COVID-19 confirmed by Polymerase Chain Reaction (PCR),
  3. salivary carriage of COVID-19 virus
  4. ability to perform mouthwash rinses and to expectorate.

Exclusion Criteria:

  1. allergy to any study mouth rinse,
  2. active uncontrolled thyroid disease,
  3. pregnancy
  4. patients undergoing radioactive iodine therapy.

Sites / Locations

  • The Ohio State University Wexner Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1% Hydrogen Peroxide Mouth Rinse

0.12% Chlorhexidine Gluconate Mouth Rinse

0.5% Povidone Iodine Mouth Rinse

0.9% Normal Saline Mouth Rinse

Arm Description

30 second oral rinse with 1% Hydrogen Peroxide

30 second oral rinse with 0.12% Chlorhexidine Gluconate

30 second oral rinse with 0.5% Povidone Iodine Mouth wash

30 second oral rinse with 0.9% Normal Saline

Outcomes

Primary Outcome Measures

real time reverse transcriptase quantitative PCR
Saliva load was expressed in copies x 10 8 of COVID-19 RNA
ct values
cycle thresholds

Secondary Outcome Measures

Full Information

First Posted
October 21, 2020
Last Updated
October 23, 2020
Sponsor
Ohio State University
search

1. Study Identification

Unique Protocol Identification Number
NCT04603794
Brief Title
Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19
Official Title
Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2020 (Actual)
Primary Completion Date
November 2020 (Anticipated)
Study Completion Date
November 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio State University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Researchers know that the virus that causes COVID-19 has been found in the saliva (spit) of individuals who exhibit signs of the disease. Investigators would like to test the ability of three mouthwashes to reduce the levels of this virus in participants' mouths. Investigators will ask participants to use a liquid to swish around in the mouth for 30 seconds and spit it into a collection cup. Investigators will also collect spit from participants before and after participants use the mouthwash. Although participants will have no direct benefits from the study, investigators will gain a wealth of information that would benefit patients who are at risk for COVID-19.
Detailed Description
Project aims: Aim 1: To examine the salivary carriage of COVID-19 in individuals before and after use of mouthwashes known to reduce oral microbiota, using real time reverse transcriptase quantitative PCR (Polymerase Chain Reaction) to quantify viral load. RESEARCH STRATEGY: A. Recruitment and baseline data: This is a cross-sectional interventional 4 arm study. 60 subjects between 18-80 years of age will be recruited from those who are being treated for COVID-19 at the Ohio State University Medical Center. There is no data upon which to base sample size estimates, and investigators have landed on this number in an effort to obtain a representative sample of Ohio's population. If the potential subject is interested in participating, the study coordinator will collect contact information from the candidate and the consent form will be presented to these individuals. Subjects will be allowed sufficient time to read and ask questions, and once sign these forms, a detailed history including information about ethnicity, education, income, age, sex, race, medical status (including pregnancy) and dental history will be elicited. Subjects will self-collect saliva in a 5 ml collection tube, following which they will be asked to use one of 3 mouthwashes (chlorhexidine, povidone iodine, hydrogen peroxide or control(saline) for thirty seconds and spit them into collection tubes. Investigators will use Peridex, Hydrogen Peroxide and Betadine, which are commercially available formulations of chlorhexidine, hydrogen peroxide and betadine respectively, to reduce formulation bias. Investigators have attached the product labels as appendices to this proposal. The exact mouthwash will be decided by random chance using a random number generator. Investigators have generated the following randomization schedule using Microsoft excel: Each subject will be assigned a number as they are recruited (E.g. first patient to sign the consent will be patient 1, and the second will be patient 2 and so on). Patients 1 and 2 will receive saline and 3 will receive chlorhexidine etc. base on the above randomization schedule. Subjects will then collect saliva in separate collection tubes 15 and 30 minutes after rinsing. B. Sample collection Saliva will be collected using a methodology described by previous investigators. Briefly, subjects will be asked to collect saliva in their mouth for 3 minutes and then continuously drool into a tube for 3 minutes. This method will allow investigators to collect unstimulated saliva. Saliva will be collected using kits containing RNA (Ribonucleic Acid) stabilizer (Oragen RNA kit). C. Measurement / Instrumentation Total RNA will be isolated from saliva using the mirVana miRNA (Messenger Ribonucleic Acid) isolation kit (Applied Biosystems). Microbial cells will be lysed and RNA will be extracted by Acid-Phenol:Chloroform and ethanol precipitation and eluted in nuclease-free water. Investigators will use well validated primers to quantify copy numbers of COVID-19 spike protein mRNA (Messenger Ribonucleic Acid) from the saliva. For an absolute quantification of COVID-19, investigators will use one step RT-PCR (Reverse Transcriptase) assay by using an appropriate commercially available kit. In this step investigators will convert mRNA to cDNA (complementary Deoxyribonucleic Acid) and then quantify the cDNA by using targeted primers and then copy numbers of the COVID-19 will be calculated by comparing ct (cycle threshold)Values samples against standard curve. In order to generate standard curves for absolute quantification, target genes will be amplified with PCR. The PCR products will be cloned into suitable vector. Then plasmids will be extracted, serially diluted, and used as templates in qPCR (quantitative polymerase chain reaction) for generating standard curves. D. Internal Validity Subjects will be recruited randomly through voluntary participation. This will eliminate presentation bias. E. Data Analysis Descriptive statistics will be provided as estimates of salivary carriage of COVID-19. Frequency of salivary carriage of the virus will be expressed as a percent of the total sample population. Reduction in COVID-19 following mouthwash use will be expressed as fold change and compared between the three mouthwash groups using parametric tests.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
Mouthwashes, COVID-19, Salivary Carriage, Povidone-Iodine, PCR (Polymerase Chain Reaction), Dental Aerosols

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
This randomized, cross-sectional, double blinded, negative controlled, four armed, prospective, interventional study compared Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in 60 subjects being treated for Covid 19 at the The Ohio State University Medical Center. Real time reverse transcriptase quantitative PCR measured viral loads.
Masking
ParticipantCare ProviderInvestigator
Masking Description
Double Blinded. All mouthwash vials are masked.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1% Hydrogen Peroxide Mouth Rinse
Arm Type
Active Comparator
Arm Description
30 second oral rinse with 1% Hydrogen Peroxide
Arm Title
0.12% Chlorhexidine Gluconate Mouth Rinse
Arm Type
Active Comparator
Arm Description
30 second oral rinse with 0.12% Chlorhexidine Gluconate
Arm Title
0.5% Povidone Iodine Mouth Rinse
Arm Type
Active Comparator
Arm Description
30 second oral rinse with 0.5% Povidone Iodine Mouth wash
Arm Title
0.9% Normal Saline Mouth Rinse
Arm Type
Placebo Comparator
Arm Description
30 second oral rinse with 0.9% Normal Saline
Intervention Type
Drug
Intervention Name(s)
0.5% Povidone Iodine
Other Intervention Name(s)
Betadine Mouthwash
Intervention Description
Commercially Available Mouth Rinses and Over the Counter Standard Formulations
Intervention Type
Drug
Intervention Name(s)
0.12% Chlorhexidine Gluconate Mouth Rinse
Other Intervention Name(s)
Peridex
Intervention Description
Commercially Available Mouth Rinses
Intervention Type
Drug
Intervention Name(s)
1% Hydrogen Peroxide
Other Intervention Name(s)
Hydrogen Peroxide
Intervention Description
Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Intervention Type
Drug
Intervention Name(s)
0.9% Normal Saline
Other Intervention Name(s)
Salt Water
Intervention Description
Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Primary Outcome Measure Information:
Title
real time reverse transcriptase quantitative PCR
Description
Saliva load was expressed in copies x 10 8 of COVID-19 RNA
Time Frame
3 measurements of changes from times 0 minutes. vs:15 minutes, and vs: 45 minutes during a single session
Title
ct values
Description
cycle thresholds
Time Frame
3 measurements of changes from times 0 minutes.vs:15 minutes, and vs:45 minutes during a single session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adults age 18-80 admitted to The Ohio State University Medical Center, diagnosis of COVID-19 confirmed by Polymerase Chain Reaction (PCR), salivary carriage of COVID-19 virus ability to perform mouthwash rinses and to expectorate. Exclusion Criteria: allergy to any study mouth rinse, active uncontrolled thyroid disease, pregnancy patients undergoing radioactive iodine therapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David L Hall, DDS
Phone
614-292-2622
Email
hall.611@osu.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Purnima Kumar, PhD,DDS
Phone
614-804-2112
Email
kumar.83@osu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David L Hall, DDS
Organizational Affiliation
The Ohio State University College of Dentistry
Official's Role
Study Director
Facility Information:
Facility Name
The Ohio State University Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David L Hall, DDS
Phone
614-292-2622
Email
hall.611@osu.edu
First Name & Middle Initial & Last Name & Degree
Purnima Kumar, PhD,DDS
Phone
614-804-2112
Email
kumar.83@osu.edu

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
As per The Ohio State University Office for Responsible Research Practices (Human Studies IRB)
Citations:
PubMed Identifier
24340537
Citation
Serban D, Banu A, Serban C, Tuta-Sas I, Vlaicu B. Predictors of quantitative microbiological analysis of spatter and aerosolization during scaling. Rev Med Chir Soc Med Nat Iasi. 2013 Apr-Jun;117(2):503-8.
Results Reference
background
PubMed Identifier
23855840
Citation
Gupta G, Mitra D, Ashok KP, Gupta A, Soni S, Ahmed S, Arya A. Efficacy of preprocedural mouth rinsing in reducing aerosol contamination produced by ultrasonic scaler: a pilot study. J Periodontol. 2014 Apr;85(4):562-8. doi: 10.1902/jop.2013.120616. Epub 2013 Jul 15.
Results Reference
background
PubMed Identifier
24685786
Citation
Shetty SK, Sharath K, Shenoy S, Sreekumar C, Shetty RN, Biju T. Compare the effcacy of two commercially available mouthrinses in reducing viable bacterial count in dental aerosol produced during ultrasonic scaling when used as a preprocedural rinse. J Contemp Dent Pract. 2013 Sep 1;14(5):848-51. doi: 10.5005/jp-journals-10024-1414.
Results Reference
background
PubMed Identifier
23250175
Citation
Devker NR, Mohitey J, Vibhute A, Chouhan VS, Chavan P, Malagi S, Joseph R. A study to evaluate and compare the efficacy of preprocedural mouthrinsing and high volume evacuator attachment alone and in combination in reducing the amount of viable aerosols produced during ultrasonic scaling procedure. J Contemp Dent Pract. 2012 Sep 1;13(5):681-9. doi: 10.5005/jp-journals-10024-1209.
Results Reference
background
PubMed Identifier
12024755
Citation
Klyn SL, Cummings DE, Richardson BW, Davis RD. Reduction of bacteria-containing spray produced during ultrasonic scaling. Gen Dent. 2001 Nov-Dec;49(6):648-52.
Results Reference
background
PubMed Identifier
17214015
Citation
Wirthlin MR, Choi JH, Kye SB. Use of chlorine dioxide mouthrinse as the ultrasonic scaling lavage reduces the viable bacteria in the generated aerosols. J West Soc Periodontol Periodontal Abstr. 2006;54(2):35-44. No abstract available.
Results Reference
background
PubMed Identifier
32127517
Citation
Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020 Mar 3;12(1):9. doi: 10.1038/s41368-020-0075-9.
Results Reference
background
PubMed Identifier
8215087
Citation
Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci. 1993 Sep 20;694:72-7. doi: 10.1111/j.1749-6632.1993.tb18343.x. No abstract available.
Results Reference
background
PubMed Identifier
32047895
Citation
To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Chik TS, Choi CY, Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF, Yuen KY. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis. 2020 Jul 28;71(15):841-843. doi: 10.1093/cid/ciaa149.
Results Reference
background
PubMed Identifier
34561086
Citation
Chaudhary P, Melkonyan A, Meethil A, Saraswat S, Hall DL, Cottle J, Wenzel M, Ayouty N, Bense S, Casanova F, Chaney M, Chase H, Hermel R, McClement M, Sesson C, Woolsey B, Kumar P. Estimating salivary carriage of severe acute respiratory syndrome coronavirus 2 in nonsymptomatic people and efficacy of mouthrinse in reducing viral load: A randomized controlled trial. J Am Dent Assoc. 2021 Nov;152(11):903-908. doi: 10.1016/j.adaj.2021.05.021. Epub 2021 Jun 11.
Results Reference
derived
Links:
URL
https://doi.org/10.21203/rs.3.rs-34544/v2
Description
Povidone-iodine demonstrates rapid in-vitro Activity...
URL
https://doi.org/10.1016/j.ijid.2020.05.030
Description
Viral dynamics in asymptomatic patients with COVID-19

Learn more about this trial

Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19

We'll reach out to this number within 24 hrs